4th Annual Epigenetics Congress: Solutions to Challenges like Drug Discovery, Identification of Molecular Inhibitors, Gene Modification, and Analysis (London, United Kingdom - October 3-4, 2019) - ResearchAndMarkets.com
While most of the molecular studies focus over mutational analysis, epigenetics-is the only science which is gaining momentum with its cheaper and faster technology, by making its way to the clinic. Moving on the path of clinical epigenetics, this congress will discuss the solutions to challenges like drug discovery, identification of molecular inhibitors, gene modification, and analysis.
users
Learn from academia and industry experts about clinical epigenetics, discussing solutions to challenges like drug discovery, identification of molecular inhibitors, gene modification, and analysis.
Our expert speaker panel will address the emergence of novel drugs and next-generation diagnostic technologies with respect to huge growth, government funding for epigenetics research. The congress will host an effective mix of case studies, panel discussion, and presentations on the development of epigenetics, translational epigenetics, clinical epigenetics and more.
users
Engage with pioneers and leaders from academia and industry and stay updated with the latest advancement in epigenetics research right from drug discovery to the identification of molecular inhibitors to gene modifications and analysis.
Agenda:
Day 1
DEVELOPMENT OF EPIGENETICS
Emerging Portfolio of Novel Epigenetic Inhibitors 09:10 - 09:35 Daniel Dransfield, Vice President, Biology, Epizyme
High-resolution economical profiling of epigenetic DNA modifications using TOP-seq 09:35 - 10:00 Saulius Klimasauskas, Director and Distinguished Professor, Institute of Biotechnology, Vilnius University
Robust Sample Preparation Solutions for Chromatin-based Applications 10:00 - 10:30 Angela Garding, Field Application Scientist, Epigenomics, Covaris
Importance of investigating epigenetic alterations for industry and regulators 11:20 - 11:45 Rmi Terranova, Principle Investigator, Preclinical Safety, Novartis Institutes for BioMedical Research, Switz
Drugging transcription: Progress and potential for treating human immune dysfunction 11:45 - 12:10 Inma Rioja, Senior Director & Portfolio Research Lead at Epige, GSK
TRANSLATIONAL EPIGENETICS
Making sense of disease-linked non-coding mutations 12:10 - 12:35 Mikhail Spivakov, Group leader and Honorary Senior Lecturer, MRC Lon, Imperial College
Panel Discussion: Comparison of old traditional approach to inhibitor specific method 14:05 - 14:30
HDACs as potential drug targets in airway inflammation 14:30 - 14:55 Prof. Frank Dekker, Professor, Medicinal Chemistry, Chemical Biology, University of Groningen, Netherlands
Selective' targeting of transcriptional scaffolding 14:55 - 15:20 Panagis Filippakopoulos, Associate Professor, Structural Genomics Consortium, University of Oxford
Solution provider presentation - To book this slot, email us on [email protected] 15:20 - 15:50
Epigenetics inhibitors for methylation 16:40 - 17:05
Incorporation of epigenetics in a risk assessment framework 17:05 - 17:30
Analyzing the potential of immunoepigenetic modulators 17:30 - 17:55
Closing Remarks by the Chair 17:55 - 18:00
End of Day 1 18:00 - 18:10
Day 2
CLINICAL EPIGENETICS
Epigenetics in drug discovery: a fresh perspective? 09:10 - 09:35 Rachel Grimley, Executive Director, Global Head, Mechanistic Biology, AstraZeneca
DNA methylation as an epigenetic factor in psychiatric disorders and their treatment 09:35 - 10:00 Gavin Reynolds, Professor Emeritus, Queens University Belfast
LSD1 inhibitors Iadademstat and Vafidemstat from bench to bedside 10:00 - 10:30 Dr. Tamara Maes, Chief Scientific Officer, Oryzon, Spain
Epigenetic Marks in inflammatory diseases; relevance for precision medicine development 11:40 - 12:05 Wouter De Jounge, Professor, NARCIS, Netherlands
Challenges in targeting histone demethylases 12:05 - 12:30 Christopher Schofield, Head of Organic Chemistry, University of Oxford and fellow of Royal Society
Probing HDACs and bromodomains in cancer with small molecule designer libraries 14:00 - 14:20 John Spencer, Professor, Bioorganic Chemistry, University of Sussex
Development of novel therapeutic anticancer approach with HDAC inhibitors: from the bench to the bedside 14:20 - 14:45 Alfredo Budillon, Chief Experimental Pharmacology Unit Department of, Istituto Nazionale tumori G. Pascale
Pancreatic islet chromatin dynamics and type 1 diabetes genetic architecture 14:45 - 15:10 Lorenzo Pasquali, Group Leader of the Endocrine Regulatory Genomics laboratory, IGTP
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...
Although gun violence is down by 12%, gun-related homicide is up by 44%. Therefore, the City of Lauderhill is announcing a pivotal strategy to reduce gun violence and promote peace among its 75,000 residents. This plan highlights Lauderhill's...
Specsavers was recognized in Canada's Best Workplacestm List for 2024 by Great Place To Work®, the global authority on workplace culture. The Company is proud to rank as the highest optical retailer in the medium-sized company category after entering...
St. Joseph's Hospital today announced that it becomes the first health care facility to use checkout-free technology in a hospital cafeteria, demonstrating BayCare and St. Joseph's Hospital's commitment to innovation, patient care and team member...
Veterans with Wounded Warrior Project® (WWP) kicked off the organization's annual Soldier Ride® in the nation's capital with First Lady Jill Biden at the White House today. As part of her Joining Forces initiative to support military and veteran...
Tiger Aesthetics Medical, LLC today announced its acquisition of substantially all of the assets associated with the Sientra Inc. breast implant business. This strategic acquisition will complement Tiger Aesthetics' upcoming adipose cell and tissue...